CRP and myasthenia gravis: The immunomodulatory feature of MEPED was demonstrated by a significant decrease in C-reactive protein (CRP) in serum during objective response (Ugocsai et al., 2016), as well as a robust neurological improvement in a patient with severe myasthenia gravis who did not qualify for dose-intensive therapy (Fichtner et al., 2020).